You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
重藥控股(000950.SZ):2019年度淨利潤升14.09%至7.88億元
格隆匯 04-16 19:59

格隆匯4月16日丨重藥控股(000950.SZ)披露2019年年度報告,實現營業收入338.44億元,同比增長31.16%;歸屬於上市公司股東的淨利潤7.88億元,同比增長14.09%;歸屬於上市公司股東的扣除非經常性損益的淨利潤7.21億元,同比增長13.51%;基本每股收益0.46元,擬向全體股東每10股派發現金紅利0.5元(含税)。

報告期內,公司面臨宏觀經濟增速放緩和醫藥行業變革加劇、醫療改革全面深化的現狀,特別是“4+7”帶量採購的推行,對整個醫藥產業鏈變革產生了重要的影響。公司主動適應日益嚴峻的改革發展壓力,聚焦主業、深化改革、創新發展;同時,繼續有序推進業務內生增長與外延擴張,加強集約化發展和創新轉型,完善戰略產業佈局,區域協同發展成效日益明顯。2019年度,公司較好的完成了全年經營目標,業績增幅再創新高,為2020年“十三五”規劃收官之年奠定了堅實的基礎。

面對醫藥流通領域更加激烈的競爭,集中度的進一步提高,公司通過剖析自身的優劣勢,結合行業環境,實時調整和修改發展戰略實施路徑和目標。未來,公司將繼續着力打造多元業務模式、多元發展目標和多元實現路徑的發展模式,實現資本、品牌、產品、營銷、服務等整體競爭力的全面提升,力爭成為全國具有影響力的優質醫藥供應鏈服務提供商、創新藥品製造商和醫養健康產業引領者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account